RemeGen surged 8% in Hong Kong on massive H1 profit turnaround
HK Stock Market Update·
Remegen surges 9% on swing to H1 profit, AbbVie licensing boost
HK Stock Market Update·RemeGen reports RMB 3.84 billion cash balance as of June 30, 2026 in H1 presentation
PUBT·- RemeGen reported a cash balance of RMB 3.84 billion and domestic drug sales of RMB 1.4 billion for H1 2026. - The company highlighted commercial portfolios like telitacicept and disitamab vedotin, alongside global partnerships with potential value exceeding USD 12 billion. - Key clinical updates included Phase 3 readouts for telitacicept, notably showing a 55% placebo-adjusted 24-hour UPCR reduction in the IgAN study.RemeGen climbs 5% in Hong Kong trading on rapid intraday rally
HK Stock Market Update·RemeGen climbs 5% in Hong Kong trading on mRNA vaccine catalyst
HK Stock Market Update·From Power Grids to AI Data Centers: How Hong Kong Equities Are Pivoting in 2026
Global Report·- In the summer of 2026, Hong Kong-listed companies are actively driving strategic transformations amid shifting economic narratives. - Traditional and emerging sectors are evolving, with Weichai Power entering AI data center power equipment, ZTE launching a major computing center, and CLP Holdings reporting a net profit of 5.997 billion HKD. - Additional adjustments span from ASMPT's semiconductor rebound and Kintor Pharmaceutical's commercialization efforts to supply chain logistics operations.RemeGen (9995.HK) surges 8% in Hong Kong on interim profit forecast
HK Stock Market Update·Rongchang Biologics surges 8% as H1 profit forecast shows turnaround
HK Stock Market Update·